o-The recurrence rate of pituitary adenomas has been reported to be as high as 10% to 35% despite their generally benign nature. A monoclonal antibody directed against proliferating cell nuclear antigen (PCNA) was used to investigate whether the proliferative index might help to predict adenoma recurrence. This antigen is a nuclear protein identified as the auxiliary protein of deoxyribonucleic acid polymerase 6, and its gene expression correlates with cell proliferation. The authors studied 30 patients with recurrent pituitary adenomas, 32 with nonrecurrent adenomas, and seven normal pituitary tissue samples. The mean interval to recurrence (+_ standard error of the mean) was 5.3 + 0.7 years. The age-and sex-matched nonrecurrent group had a mean follow-up period of 6.6 _+ 0.3 years without clinical recurrence. Mean percentages of PCNA-positive tumor nuclei in both the initial and the second surgical specimens of the recurrent adenomas (13.45% _+ 3.132% and 19.56% 4-3.66%, respectively) were significantly higher than that of the nonrecurrent group (2.49% + 1.21%). In addition, recurrent tumors had a higher PCNA index than the initial tumors in the same patients. Normal anterior pituitary gland tissue had a significantly lower mean PCNA index (0.12% +_ 0.11%) than either patient group. Stepwise multivariate regression analysis indicated that factors which collectively correlated significantly with recurrence were: high PCNA index, large tumor size, extrasellar extension, and incomplete surgical excision. The PCNA nuclear count was not associated with age, sex, or hormone hypersecretion, but was higher in macro-than in microadenomas, in tumors with extrasellar extension, and in those incompletely excised. A higher PCNA index also correlated with a shorter disease-free interval. The authors conclude that evaluation of the PCNA index assists in predicting the likelihood of pituitary adenoma recurrence.
A

DVANCES in pituitary microsurgery have made it
possible to completely excise most microadenomas, but total removal of pituitary macroadenomas is often difficult, particularly those with extrasellar extension. Reportedly, 10% to 35% of pituitary adenomas recurred within an interval of 4 to 20 years.t~
The size of the tumor, the extent of surgical resection, and the rate of tumor regrowth are thought to be determining factors in recurrence.
Cell kinetics data have proved useful in the evaluation of tumor progression and long-term outcome? 6 Recently, such information has been acquired for several types of central nervous system tumors ~8'2~ but is still lacking for pituitary adenomas. Among various techniques used to evaluate the kinetics of tumor cells, the availability of monoclonal antibodies to cell cyclerelated antigens has provided a rapid and simple approach to measure the growth fractions in tumor sections with excellent histological preservation. The current study used the monoclonal antibody 19A2 raised against proliferating cell nuclear antigen (PCNA) 24 to evaluate the proliferative index in formalin-fixed, paraffin-embedded pituitary adenoma tissue.
Proliferating cell nuclear antigen, an acidic nuclear protein with a molecular weight of 36,000, 2~ is synthesized in the late G~ and S phases of the cell cycle; 4-7 it is the auxiliary protein of deoxyribonucleic acid (DNA) polymerase ~ and is involved in DNA replication. 3"5"7"14"2728"33'37 Studies have demonstrated that PCNA immunoreactivity correlates with mitotic activity and tumor grade in solid human malignancies; 3~ therefore, it is a potentially useful marker for proliferating cells. In this study, we assessed the utility of the PCNA index along with other clinical and pathological variables as predictors for the recurrence of pituitary adenomas. * Abbreviations: + = feature present; -= feature absent; NF = clinically nonfunctioning adenoma; PRL = prolactin-secreting tumor; GH = growth hormone-secreting tumor; ACTH = adrenocorticotropic hormone.
t Gross total tumor removal based on visual assessment at the time of surgery and on postoperative magnetic resonance imaging. Postoperative therapy given following the initial pituitary surgery.
Clinical Material and Methods
Profile of Patients With Recurrent Pituitary Adenomas
For the purpose of this study, the following criteria were used to define adenoma recurrence: for hormonesecreting adenomas, initial surgical cure was defined as no evidence of hormonal hypersecretion postoperatively; for clinical nonfunctioning tumors lacking hormone markers, an adenoma was considered recurrent when its regrowth resulted in a second surgical resection. The initial tumor was considered to be either subtotally or totally removed based on visual assessment at the time of surgery and on postoperative magnetic resonance (MR) imaging.
From 580 consecutive surgical pituitary resections performed between 1984 and 1992, 30 patients were identified as having been operated on more than once at the Massachusetts General Hospital for a pituitary tumor (Table l) . The interval between the initial and the second surgical procedures ranged from 4 months to 16 years (mean duration 5.3 _+ 0.7 years, _+ standard error of the mean). There were 17 women and 13 men, with a mean age of 43.23 _+ 2.35 years at the time of their first pituitary operation. Of these, five presented with acromegaly, three with Cushing's disease, 21 with clinically nonfunctioning pituitary adenoma, and one with a prolactin-and growth hormone-secreting tumor. At initial presentation, 29 of the 30 patients harbored macroadenomas (widest diameter > 1 cm) based on preoperative computerized tomography scans or MR images; 28 of these tumors had extrasellar extension. Twenty patients underwent subtotal removal of the tumor; 10 of the 20 received postoperative radiation therapy (4500 to 5000 cGy over 25 to 30 fractions) while two were given bromocriptine. Two of the 10 patients who underwent gross total removal of their tumor received postoperative radiation therapy (Table  1) . Decisions regarding postoperative therapy were made on an individual basis by the patients' personal physicians.
Profile of Patients With Nonrecurrent Pituitary Adenomas
Thirty-two patients were identified who underwent a single pituitary tumor resection at the Massachusetts General Hospital between 1982 and 1985 and remained in remission for at least 4 years (mean follow-up period Table 2) . Parameters considered were the lack of symptomatic recurrence and visual field disturbance. The selection of patients was based on the availability of the tumor tissue and clinical data, including a recent follow-up evaluation. Follow-up data were obtained from office notes, telephone contact, or patients' response to a 1990 questionnaire. There were 23 women and nine men, with a mean age of 44.16 + 3.14 years. Of these, six were acromegalic, nine had Cushing's disease, 12 harbored nonfunctioning pituitary tumors, and five had prolactinomas. Twenty-one patients presented with macroadenomas, 19 of which had extrasellar extension. Twelve patients underwent subtotal removal, eight of whom received postoperative radiation therapy. Among the 20 patients with gross total removal of their tumors, two of the nine with macroadenomas and one of the 11 with microadenomas also received postoperative radiation therapy. One of the six acromegalic patients was given bromocriptine following gross total tumor removal ( Table 2 ). Three of the five patients presenting with prolactinomas received preoperative bromocriptine therapy without benefit. Included in the nonrecurrent tumor group were two patients with invasive macroadenomas who underwent subtotal removal of their tumor and postoperative radiation therapy, and were asymptomatic at the time of a recent follow-up review 6 and 7 years after initial surgery.
Tumor Characteristics
Among the 29 recurrent macroadenomas, six were grossly invasive, showing erosion through the sellar floor; 10 of these tumors had cystic components (Table  1) . Routine immunocytochemical analysis for anterior pituitary hormones revealed that all five tumors associated with acromegaly contained growth hormoneimmunoreactive cells; four of these cases also had prolactin-immunoreactive cells, and two of these were also immunoreactive to the alpha subunit of the glycoproteins. The three tumors associated with pituitary Cushing's disease were all immunoreactive to adrenocorticotropic hormone (ACTH). Eleven of the 21 nonfunctioning adenomas contained at least one of the subunits of the glycoprotein hormones, and one was a silent ACTH tumor.
Among the 21 macroadenomas that did not recur, two were highly invasive as described above and another two appeared cystic ( Table 2 ). Six of the 12 nonfunctioning adenomas in this group expressed cells immunoreactive to the subunits of the glycoprotein hormones.
No microadenoma was cystic. Among the 11 nonrecurrent microadenomas, two were prolactinomas, two were associated with acromegaly, and seven were ACTH tumors ( Table 2 ). All had the same immunocytochemical characteristics as described above.
Control Materials
Paraff• blocks containing surgically resected normal anterior pituitary gland tissue at the margin of tumors from seven different patients were used as negative control materials, based on the assumption that this tissue would not contain proliferating cells. Sections from five adenocarcinomas of the colon served as positive control materials for PCNA immunoreactivity. Germinal centers of the lymph nodes present in the colonic specimens provided additional positive control materials? 5 All tissues used were surgically resected, formalin-fixed, routinely processed, and paraffin-embedded. Both positive and negative control materials were included in each staining run for PCNA in pituitary tumors.
lmmunocytochemistry for PCNA
Paraffin-embedded 6-# sections of the initial and the recurrent biopsies were deparaffinized and rehydrated. Nonspeeific reactions were blocked by incubating the sections with normal goat serum.* Tissue sections were then incubated with the anti-PCNA monoclonal antibody 19A2t for 50 minutes at room temperature (optimum dilution 1:50). This monoclonal antibody is a * Normal goat serum supplied by Vector Laboratories, Burlingame, California.
t Monoclonal antibody 19A2 supplied by Coulter Immunology, Hialeah, Florida, currently available from BioGenex, San Ramon, California. murine immunoglobulin (Ig)M antibody originally developed and characterized by Ogata, et at. 24 '25 Following a thorough wash with phosphate-buffered saline (PBS), the endogenous peroxidase activity was blocked with methanol containing 0.3% H202 for 20 minutes. Sections were then incubated with a biotin-conjugated, anti-IgM, mu-chain-specific secondary antibody, followed by peroxidase-conjugated streptavidin.~ Each step was followed by thorough washes with PBS. The antigen-antibody binding was detected with 3,3'-diamino-benzidine/H202, and sections were counterstained with hematoxylin, dehydrated, cleared, and mounted.
Determining the PCNA Index
All cell counts were carried out at x 400 magnification with the aid of an ocular grid reticle, without knowledge of the group to which the tumor belonged. With the exception of very large tumors, nuclear counts were taken from at least half of the total sectional area of the tumors, beginning with the areas having the highest density of PCNA-positive cells. Labeled nuclei were counted as positive regardless of the staining intensity. The method of counting labeled nuclei in areas with the highest density was thought to offer reduced subjectivity. ~s,22 A total of 500 to 2000 nuclei in up to seven fields were counted for each specimen, depending on the size of the available tumor area. A PCNApositive cell fraction was expressed as the percentage of labeled nuclei in the total tumor nuclei counted per section. Vascular endothelial cells and non-neoplastic cells were not counted.
Statistical Analysis
Data were analyzed statistically with Student's t-test, Mann-Whitney U-test, Wilcoxon signed-rank test, chisquared tabulation, analysis of variance, and stepwise multivariate regression using the Numbercruncher staSecondary antibody and streptavidin supplied by Jackson Laboratories, Inc., West Grove, Pennsylvania. tistical package interfaced with an IBM personal computer. Comparisons were made between the recurrent and the nonrecurrent groups with regard to clinical profile, tumor characteristics, and PCNA index. A p value less than 0.05 was considered statistically significant.
Results
PCNA lmmunoreactivity in Control Materials
The highly proliferative neoplastic colonic specimens showed strong nuclear reactivity in more than half of the adenocarcinomatous cells (Fig. 1A) . Normal proliferative compartments, such as the germinal centers of the lymph nodes, contained numerous (> 50%) strongly stained nuclei (Fig. 1B) . In the non-neoplastic colonic epithelium, positive nuclei were found scattered only in the basal layer. In agreement with Kamel, et al., 's we found that the anti-IgM mu-chain-specific secondary antibody greatly enhanced the sensitivity of the reaction. Although the staining intensity varied, the positive nuclei were usually distinct and easily distinguished from the negative ones. By contrast, the seven normal pituitary tissue specimens showed only occasional PCNA-positive nuclei (mean 0.12% _+ 0.1 I%). Vascular endothelial cells were negative to PCNA.
PCNA-Posilive Cell Fractions in Pituitary Adenomas
Immunoperoxidase staining for PCNA in pituitary tumors revealed positive fractions ranging from 0% to greater than 50%. Most of the tumors that contained high numbers of PCNA-positive nuclei had a diffuse distribution of these cells throughout the tumor. However, regional variation existed in many cases, with some showing only focal areas with positive nuclei. The nuclear reactivity was generally very intense; however, a gradation of intensity between cells in a given tumor was also observed, corresponding with the different levels of PCNA expressed during cell-cycle phases. Mitotic figures were only faintly positive for PCNA (Fig. 2) .
Among the 30 recurrent pituitary adenomas, 27 (90%) exhibited PCNA-positive nuclear fractions greater than 5% in at least one of the two surgical specimens obtained from each patient, while only two cases (6.7%) had a PCNA index of less than 1%. The mean percentage of PCNA-positive nuclei was 13.45 % __+ 3.02% (range 0% to 64.39%) for the patients' initial tumors and 19.56% _ 3.66% (range 0% to 84.54%) for their recurrent tumors. By contrast, only three (9.4%) of the 32 cases in the nonrecurrent group had a PCNA index greater than 5%, 17 cases (53%) had 0%, and eight cases (25%) showed less than 1%. The mean percentage for the nonrecurrent group was 2.49% +_ 1.21% (range 0% to 29.21%). The frequency distribution of these nuclear counts is summarized in Table 3 (1)) and recurrent (Recurrent (2)) tumors in patients with recurrent adenomas. Cases are grouped as having low (< 1%), moderate (1% to 5%), or high (> 5%) PCNA-positive nuclear fractions.
and Fig. 3 . The mean PCNA value of the recurrent group was significantly higher than that of the nonrecurrent group (p < 0.0001, Mann-Whitney test), and the recurrent tumors had a significantly higher PCNA index (p < 0.05, Wilcoxon signed-rank test) than the initial tumors in the same patients (Fig. 4) .
Factors Contributing to Recurrence
By chi-squared analysis, the two patient groups had the same distribution of age, gender, and disease-free interval/follow-up period (Table 4) . However, there was a higher proportion of cystic tumors in the recurrent group than in the nonrecurrent group (chi-squared test = 7.28, 1 df, p < 0.01). The recurrent group also had significantly higher numbers of macroadenornas (chisquared test = 9.56, 1 df, p < 0.005) and tumors with extrasellar extension (chi-squared test = 9.74, 1 dr, p < 0.005) than the nonrecurrent group. Incomplete surgical excision was also more frequent in the recurrent group (chi-squared test = 5.27, 1 dr, p < 0.05) ( Table  4) . Stepwise multivariate regression analysis revealed factors that collectively correlated significantly with recurrence: high PCNA index, macroadenoma, extrasellar extension, and incomplete surgical excision (r = 0.64, F ratio = 4.87, df = 7/50, p < 0.0001) ( Table 5) . Although each was not independently significant, together these factors were highly significant positive predictors of tumor recurrence, with a high PCNA index being a greater contributor than the other factors.
Chi-squared and stepwise multivariate regression analyses did not indicate an association of recurrence with tumor subtype based on the hormone status. A1- (1)) and recurrent (Recurrent (2)) tumors in patients with recurrent adenomas. Lines above the bars indicate standard error of the mean, and asterisks indicate statistically significant differences: see text.
though there were fewer cystic tumors in the nonrecurrent group, PCNA nuclear counts were not different between adenomas with cystic components and those without (Table 5 ). Analysis showed that the PCNA value did not correlate with patient age, but correlated inversely with the interval to recurrence, that is, a higher PCNA index was associated with a shorter disease-free interval (r = 0.34, F ratio = 6.42, df = 1/48, p < 0.05).
PCNA lndex and Postoperative Management
The proportion of patients who received radiation therapy after initial surgery was statistically the same for both the recurrent and the nonrecurrent groups. In the group with recurrence, irradiated tumors had the same mean PCNA index at recurrence as those not irradiated. For the two patients who received bromocriptine after their first pituitary operation, PCNA nuclear counts also remained unchanged in the recurrent tumors from those in the initial tumors.
Discussion
Pituitary adenomas are usually benign slow-growing tumors. However, these tumors can recur and be difficult to excise completely. The rate of recurrence has recently been reported to be as high as 16% at 8 years ~ or 35% at 20 years. 29 Clinical features and histological patterns are not adequate indicators for the biological behavior and the regrowth potential of these tumors. 3~ In this report, we have demonstrated that a high proliferative index determined on routinely processed, paraffin-embedded surgical tissue using a monoclonal antibody directed against PCNA is associated with the likelihood of pituitary tumor recurrence. The combination of high PCNA index, macroadenoma, extrasellar extension, and subtotal surgical excision is a highly significant predictor of tumor recurrence.
PCNA in Proliferating Cells
Proliferating cell nuclear antigen, a nuclear protein identified as the auxiliary protein of DNA polymerase ~,~ is found to be closely involved in DNA replication and cell division. 3' 8 The distribution of PCNA during the cell cycle has been well described, 5~7"32 with the highest concentrations found in the late Gl phase and throughout the S phase 7 and lower concentrations detected in the G2 phase? TM The PCNA levels are very low in the M phase and not detectable in the Go phase.
The specificity of our detecting system with the monoclonal antibody 19A2 was demonstrated with the control materials, where normal anterior pituitary gland tissue contained virtually no proliferating cells but carcinomas and proliferative compartments of non-neoplastic tissues demonstrated high numbers of PCNApositive nuclei. The great majority of nonrecurrent pituitary adenomas contained very few PCNA-labeled cells, while most of the recurrent adenomas exhibited numerous strongly labeled nuclei.
We observed some very high proliferating cell fractions in many of the recurrent adenomas. To date, there has been no other published report on the proliferative index of recurrent pituitary tumors. Thus, our data revealed a previously unrecognized subgroup of pituitary tumors with high proliferative potential. Landolt, eta[., ~9 examined the growth rate of pituitary adenomas, but no data regarding recurrence were given. These authors used the monoclonal antibody Ki-67 on frozen sections of biopsy materials and found the percentage of Ki-67-positive nuclei to be 0.1% to 3.7%. These numbers are in agreement with our data on the nonrecurrent adenomas, with the exception of three cases. Of the three cases with exceptionally high PCNA cell counts without clinical or symptomatic recurrence in at least 6 years of follow-up monitoring, one was a completely excised ACTH-secreting tumor (Case 21, Table 2 ), one was a subtotally removed nonfunctioning tumor (Case 5) given postoperative radiation therapy, and the third was a tumor secreting growth hormone and thyroid-stimulating hormone (Case 6) treated postoperatively with experimental gonadotropin-releasing hormone analog as well as radiation therapy. Initially included in the nonrecurrent group was another case with a high PCNA index, which was later removed from the study when the patient developed evidence on MR images of tumor recurrence.
PCNA Index in Relation to Tumor Recurrence
Using stepwise multivariate regression analysis, we found a significantly higher likelihood of tumor recurrence when a high proliferative index occurred in macroadenomas with extrasellar extension and subtotal t Macroadenoma (macro) defined as > 1 cm and microadenoma (micro) _< 1 cm, measured at the widest diameter on preoperative computerized tomography scan or magnetic resonance image.
Value derived from recurrent and nonrecurrent groups combined.
excision. We also found that tumors with a higher PCNA index recurred sooner. Interestingly, the PCNA index was also significantly higher in macroadenomas than in microadenomas, higher in tumors with extrasellar extension than in those without, and higher in incompletely excised tumors. Our analysis did not indicate gender as a significant contributing factor to recurrence, although tumors in men contained higher numbers of proliferating cells. In 1982, Salmi, et al., 3~ reported that the duration of symptoms prior to the diagnosis of prolactinomas or nonfunetioning adenomas was longer in women than in men, and suggested a faster rate of tumor growth in men. The majority of relapses in their study occurred in men. They also noted that large adenomas with suprasellar extension had a higher rate of recurrence. Our data further indicated an increase in the PCNA index in recurrent adenomas compared with the initial tumors in the same patients, suggesting that tumors had become more proliferative as they recurred. By mechanisms unclear at the present time, the residual tumor cells could have either undergone genetic changes or received growth stimulation from external factors and become more proliferative.
PCNA Index in Relation to Postoperative Management
Our data did not indicate postoperative radiation therapy as either a positive or negative factor contributing to recurrence. In the recurrent group, we found that patients who received radiation therapy after their initial surgery had a trend toward a lower PCNA index in their recurrent tumors than those who received no postoperative irradiation, but the difference was not statistically significant. Previous reports have documented the association of postoperative radiation therapy with a decreased rate of recurrence in pituitary adenomas. 9'm6'3~ There is also a body of literature advocating the benefit of radiation therapy after incomplete excision of other slow-growing brain tumors, such as meningiomas. 1' 2' 26' 34 Apparently controversy still exists, and more studies are needed to assess the value of postoperative radiation therapy in relation to tumor recurrence.
Advantages of PCNA Index Measurement
In addition to immunocytochemistry using cell cyclespecific monoclonal antibodies, other frequently used methods for studying cell kinetics in tumors include 3H-thymidine incorporation and flow cytometric analysis. Immunostaining has advantages over the other methods in that it does not require fresh, unfixed tissu :-s nor the handling of radioactive substances (as required for thymidine incorporation) and it allows visual assessment of tissue areas and provides clear evaluation of viable tumor cells, especially when necrosis is present or normal tissue is mixed with tumor areas. This method is also sensitive enough to provide data for specimens of very small sizes, as is often the case with pituitary microadenomas. Such advantages of evaluating cell kinetics along with histological interpretation cannot be offered by flow cytometry, which involves D. W. Hsu, et aL digesting tissue samples. Furthermore, the monoclonal antibody 19A2 has advantages over other widely used proliferative markers, such as Ki-67, in that it does not require the use of fresh, frozen tissue sections and therefore can be applied to routinely processed biopsy tissue and even archival materials.
Using the same monoclonal antibody (19A2) and the same anti-IgM mu-chain-speeific secondary antibody as in our study, Kamel, et al., ~5 found that the fraction of proliferating cells detected by 19A2 was similar to that detected by Ki-67, and concluded that 19A2 was a reliable marker of proliferative activity in formalinfixed tissues. Earlier, other authors had found that the PCNA labeling index was higher than both the 3H-thymidine labeling index ~z and the S-phase fraction calculated from flow cytometric DNA histograms, t3 The higher index obtained by PCNA labeling over the latter two methods could be due to the ability of the observer to count only tumor cells, without the diluting factors of nontumorous and necrotic tissues as encountered by flow cytometry, and the fact that PCNA is detectable in the late GI and G2 phases in addition to the S phase, 17' 35 while thymidine incorporation measures only cells in the S phase. This may also explain why the PCNA index is similar to the Ki-67 index, which labels the G~, S, G2, and M phases of the cell cycle but not the Go phase.
Conclusions
The PCNA index is useful in the routine analysis of cell kinetics in paraffin-embedded tissues and can provide an indicator for the proliferative potential of pituitary adenomas. Therefore, it may be used as an adjunct in determining the likelihood of recurrence and the most appropriate management approach for individual patients. Our data also raised the interesting question as to the efficacy of postoperative radiation therapy. More studies are needed to determine whether radiation therapy benefits patients with tumors showing a high PCNA index.
